ATE444372T1 - Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren - Google Patents

Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren

Info

Publication number
ATE444372T1
ATE444372T1 AT01939734T AT01939734T ATE444372T1 AT E444372 T1 ATE444372 T1 AT E444372T1 AT 01939734 T AT01939734 T AT 01939734T AT 01939734 T AT01939734 T AT 01939734T AT E444372 T1 ATE444372 T1 AT E444372T1
Authority
AT
Austria
Prior art keywords
vectors
transcomplementation
compositions
gene transfer
efficient gene
Prior art date
Application number
AT01939734T
Other languages
English (en)
Inventor
William J Ramsey
James N Higginbotham
Charles J Link
Original Assignee
Human Gene Therapy Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Gene Therapy Res Inst filed Critical Human Gene Therapy Res Inst
Application granted granted Critical
Publication of ATE444372T1 publication Critical patent/ATE444372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01939734T 2000-05-31 2001-05-31 Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren ATE444372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20824800P 2000-05-31 2000-05-31
PCT/US2001/017524 WO2001092550A2 (en) 2000-05-31 2001-05-31 Methods and compositions for efficient gene transfer using transcomplementary vectors

Publications (1)

Publication Number Publication Date
ATE444372T1 true ATE444372T1 (de) 2009-10-15

Family

ID=22773865

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939734T ATE444372T1 (de) 2000-05-31 2001-05-31 Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren

Country Status (6)

Country Link
US (2) US6875610B2 (de)
EP (1) EP1287153B1 (de)
AT (1) ATE444372T1 (de)
AU (1) AU2001265219A1 (de)
DE (1) DE60140052D1 (de)
WO (1) WO2001092550A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033029A1 (en) * 2001-10-16 2003-04-24 Magnum Therapeutics, Inc. Replication competent dual-ad vectors for vaccine and immunotherapy applications
CA2522925A1 (en) * 2003-04-29 2004-11-11 Cornell Research Foundation, Inc. Transgenic expression of a phytochrome a gene
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
EP2055316A1 (de) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirale, vektorbasierte Ansätze zur Erzeugung einer Immunantwort auf HIV bei Menschen
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
WO2009006758A1 (en) * 2007-07-10 2009-01-15 Tsinghua University Continuous and dynamical acquisition-type imaging system for small animal induced fluorescence molecule imaging
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
CN110964747A (zh) * 2019-11-26 2020-04-07 深圳市人民医院 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法
CN121428015B (zh) * 2025-12-31 2026-04-03 内蒙古大学 基于IscB/ωRNA的腺相关病毒递送系统及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
DE69531387T2 (de) 1994-08-16 2004-04-22 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US6333030B1 (en) * 1996-11-19 2001-12-25 Uab Research Foundation Chimeric retrovirus/adenovirus system
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU6149099A (en) * 1998-09-22 2000-04-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Replication deficient retroviral vector system and methods of using
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1059356B1 (de) * 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer

Also Published As

Publication number Publication date
US20060216271A1 (en) 2006-09-28
EP1287153B1 (de) 2009-09-30
US7125549B2 (en) 2006-10-24
AU2001265219A1 (en) 2001-12-11
US20020042139A1 (en) 2002-04-11
US6875610B2 (en) 2005-04-05
DE60140052D1 (de) 2009-11-12
WO2001092550A2 (en) 2001-12-06
EP1287153A2 (de) 2003-03-05
WO2001092550A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE444372T1 (de) Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
NO20065084L (no) Interferon-alfa polypeptider og konjugater
PL2012822T3 (pl) Zmodyfikowane białko heksonu adenowirusa i jego zastosowania
EP1781593A4 (de) Kationische lipide und verwendungsverfahren
MXPA03000634A (es) Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
DK1395669T3 (da) Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
WO2008028661A3 (en) Potexvirus- derived replicon
ATE536415T1 (de) Klonierung des cytochrome p450 gens von nicotiana
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
CN113330117A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
EP1465983A4 (de) Endothelstammzellen, populationen, isolierungsverfahren und verwendung davon
IL163745A (en) Use of adenoviruses mutated in the va and vaii genes for the preparation of pharmaceutical compositions for cancer treatment
WO2002027007A3 (en) Production of viral vectors
DE69942564D1 (de) Methoden und zusammensetzungen für die produktion von viruspartikeln
WO2003076583A3 (en) Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria
DE502005007057D1 (de) Verfahren zur herstellung von (s)-butan-2-ol
ATE357242T1 (de) Universell einsetzbares virus-inaktiviertes blutplasma aus teilen von plasma, das nicht von weisshäutigen stammt
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
FI20031880A0 (fi) Kasvien vastustuskykyä patogeeneja ja tuholaisia vastaan aikaansaavat proteiinit
PL372827A1 (en) Nucleotide sequence coding for a tolc containing a heterologous amino acid sequence

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties